"10.1371_journal.pone.0107744","plos one","2014-09-11T00:00:00Z","Nao Shiraishi; Atsushi Nishida; Shinji Shimodera; Tsukasa Sasaki; Norihito Oshima; Norio Watanabe; Tatsuo Akechi; Toshiaki A Furukawa; Yuji Okazaki","Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Japan; Department of Psychiatry and Behavioral Science, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan; Department of Neuropsychiatry, Kochi Medical School, Kochi University, Nanngoku, Kohchi, Japan; Laboratory of Health Education, Graduate School of Education, the University of Tokyo, Bunkyo, Tokyo, Japan; Office for Mental Health Support, Division for Counseling and Support, The University of Tokyo, Bunkyo, Tokyo, Japan; Department of Clinical Epidemiology, Translational Medical Center, National Center of Neurology & Psychiatry, Kodaira, Tokyo, Japan; Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Yoshida Konoe-cho, Sakyo-ku, Kyoto, Japan; Tokyo Metropolitan Matsuzawa Hospital, Setagaya, Tokyo, Japan","Conceived and designed the experiments: SS YO. Performed the experiments: AN SS TS NO. Analyzed the data: NS NW. Wrote the paper: NS TA TAF.","NS has a research fund from Aichi Health Promotion Foundation. NS has also received a speaking fee from Eli Lilly. AN has research funds from the Japanese Ministry of Health, Labor, and Welfare and the Japanese Ministry of Education, Science, and Technology. He has also received research grants from the Japanese Society for the Promotion of Science and Research Group for Schizophrenia Research in Japan. SS has received research funds from the Japanese Ministry of Education, Science, and Technology. He has also received speaking fees from Asahi Kasei, Dai-Nippon Sumitomo, GlaxoSmithKline, Astellas, Eli Lilly, Janssen, Meiji, Otsuka, Pfizer, and Schering-Plough. TS has research funds from the Japanese Ministry of Education, Science, and Technology. NO has no conflict of interest to declare. NW has research funds from the Japanese Ministry of Health, Labor, and Welfare and the Japanese Ministry of Education, Science, and Technology. He has also received speaking fees and research funds from Asahi Kasei, Dai-Nippon Sumitomo, Eli Lilly, GlaxoSmithKline, Janssen, Otsuka, Pfizer and Schering-Plough. TA has received speaking fees and/or research funds from Astellas, Astra-Zeneca, Dainippon-Sumitomo, GlaxoSmithKline, Meiji, MSD, Otsuka, Pfizer, Sanofi-Aventis, and Shionogi. He has received royalties from Igaku-Shoin, Nanzando and Chugai-igakusya. The Japanese Ministry of Education, Science, and Technology and the Japanese Ministry of Health, Labor, and Welfare have funded his research projects. TAF has received honoraria for speaking at CME meetings sponsored by Asahi Kasei, Eli Lilly, GlaxoSmithKline, Mochida, MSD, Otsuka, Pfizer, Shionogi and Tanabe-Mitsubishi. He is diplomate of the Academy of Cognitive Therapy. He has received royalties from Igaku-Shoin, Seiwa-Shoten and Nihon Bunka Kagaku-sha. He is on the advisory board for Sekisui Chemicals and Takeda Science Foundation. The Japanese Ministry of Education, Science, and Technology, the Japanese Ministry of Health, Labor, and Welfare, and the Japan Foundation for Neuroscience and Mental Health have funded his research projects. YO has no conflict of interest to declare. TAF is a PLOS ONE Editorial Board member. However, this does not alter the authors' adherence to PLOS ONE Editorial policies and criteria. In addition, these competing interests do not alter the authors' adherence to PLOS ONE policies on sharing data and materials.","2014","09","Nao Shiraishi","NS",9,TRUE,2,4,2,3,TRUE,TRUE,FALSE,0,NA,FALSE
